Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
JCO Precision Oncology|June 14, 2023
Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry StudyApar K Ganti, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology|June 12, 2024
Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry StudyGordan Srkalovic, Michael Rothe, Pam K Mangat, et al.
JCO Precision Oncology|November 21, 2022
Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyKelsey A Klute, Michael Rothe, Elizabeth Garrett-Mayer, et al.
Targeted Oncology|October 22, 2020
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) StudyJulie G Fisher, David Tait, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology|January 20, 2022
Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyEugene R Ahn, Pam K Mangat, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology|July 16, 2024
Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry StudyScott Schuetze, Michael Rothe, Pam K Mangat, et al.
The Lancet. Oncology|October 5, 2023
Measuring ovarian toxicity in clinical trials: an American Society of Clinical Oncology research statementWanda Cui, Rodney P Rocconi, Ramya Thota, et al.
JCO Precision Oncology|July 15, 2026
Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyDan S Veljovich, Michael Rothe, Elizabeth Garrett-Mayer, et al.
JCO Precision Oncology|February 14, 2024
Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry StudyCarmen J Calfa, Michael Rothe, Pam K Mangat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 15, 2024
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry StudyTimothy L Cannon, Michael Rothe, Pam K Mangat, et al.
Pageof 5